In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Seahorse Bioscience Inc.

Division of Agilent Technologies Inc.
seahorsebio.com

Latest From Seahorse Bioscience Inc.

Device/Diagnostics Quarterly Deal Statistics, Q3 2015

$1.4 billion in Q3 device financing was slightly lower than Q2's $1.8 billion with just one IPO versus Q2's seven. Acquisitions reached a high of $23 billion and diagnostics financing increased 30% over Q2 to $1 billion, while M&A activity at $1.2 billion showed a sharp decline from the previous quarter's $15.6 billion.

Medical Device Deals

Deals In Depth: September 2015

AstraZeneca offloaded former Amgen-partnered IL-17 antagonist brodalumab to Valeant; there was consolidation in the dental instruments industry via the $5.3bn merger of Dentsply and Sirona. Compared with August, financing in the biopharma sector was up while device was flat.

BioPharmaceutical Medical Device

Deals Shaping The Medical Industry, October 2015

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, Pharmaceuticals, and Research/Analytical Tools – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in September 2015.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • ADMET
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Agilent Technologies Inc.
  • Senior Management
  • Jay Teich, CEO
    Jeff Templer, CFO
    Steve Chomicz, VP, Sales & Mktg.
    David Ferrick, PhD, CSO
  • Contact Info
  • Seahorse Bioscience Inc.
    Phone: (978) 671-1600
    16 Esquire Rd.
    North Billerica, MA 01862
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register